ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Trivalent Split Influenza Vaccine Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-11K19190
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Trivalent Split Influenza Vaccine Market Research Report 2025
BUY CHAPTERS

Global Trivalent Split Influenza Vaccine Market Research Report 2025

Code: QYRE-Auto-11K19190
Report
February 2025
Pages:82
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Seqirus
Sanofi
GSK
SINOVAC BIOTECH
Zhejiang Tianyuan Bio-Pharmaceutical
Changchun Institute of Biological Products
Aleph Biomedical
ADIMMUNE Corporation
Shanghai Institute Of Biological Products Limited Liability Company

The global market for Trivalent Split Influenza Vaccine was valued at US$ 5207 million in the year 2024 and is projected to reach a revised size of US$ 8695 million by 2031, growing at a CAGR of 7.6% during the forecast period.

Trivalent Split Influenza Vaccine Market

Trivalent Split Influenza Vaccine Market

Trivalent Split Influenza Vaccine is a preventive biological product, which is mainly used to prevent influenza virus infection. It contains three different influenza virus strains, a subtype of influenza A (H1N1), A (H3N2) and a type B influenza virus. These strains are cleaved so that they lose their infectivity but retain their antigenicity, which stimulates an immune response in the body and thus provides protection against the corresponding influenza strain after vaccination. This vaccine is usually given before flu season to reduce the risk and severity of flu infection.
North American market for Trivalent Split Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Trivalent Split Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Trivalent Split Influenza Vaccine include Seqirus, Sanofi, GSK, Sinovac Biotech, Shanghai Institute Of Biological Products Limited Liability Company, Zhejiang Tianyuan Bio-Pharmaceutical, Changchun Institute of Biological Products, Aleph Biomedical, Adimmune Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Trivalent Split Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Trivalent Split Influenza Vaccine.
The Trivalent Split Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Trivalent Split Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Trivalent Split Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Trivalent Split Influenza Vaccine Market Report

Report Metric Details
Report Name Trivalent Split Influenza Vaccine Market
Accounted market size in year US$ 5207 million
Forecasted market size in 2031 US$ 8695 million
CAGR 7.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Injection
  • Nasal Spray
Segment by Application
  • 6 Months to 3 Years
  • > 3 Years
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Seqirus, Sanofi, GSK, Sinovac Biotech, Shanghai Institute Of Biological Products Limited Liability Company, Zhejiang Tianyuan Bio-Pharmaceutical, Changchun Institute of Biological Products, Aleph Biomedical, Adimmune Corporation
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Trivalent Split Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Trivalent Split Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Trivalent Split Influenza Vaccine Market growing?

Ans: The Trivalent Split Influenza Vaccine Market witnessing a CAGR of 7.6% during the forecast period 2025-2031.

What is the Trivalent Split Influenza Vaccine Market size in 2031?

Ans: The Trivalent Split Influenza Vaccine Market size in 2031 will be US$ 8695 million.

Who are the main players in the Trivalent Split Influenza Vaccine Market report?

Ans: The main players in the Trivalent Split Influenza Vaccine Market are Seqirus, Sanofi, GSK, Sinovac Biotech, Shanghai Institute Of Biological Products Limited Liability Company, Zhejiang Tianyuan Bio-Pharmaceutical, Changchun Institute of Biological Products, Aleph Biomedical, Adimmune Corporation

What are the Application segmentation covered in the Trivalent Split Influenza Vaccine Market report?

Ans: The Applications covered in the Trivalent Split Influenza Vaccine Market report are 6 Months to 3 Years, > 3 Years

What are the Type segmentation covered in the Trivalent Split Influenza Vaccine Market report?

Ans: The Types covered in the Trivalent Split Influenza Vaccine Market report are Injection, Nasal Spray

Recommended Reports

Influenza Vaccines

General Vaccines

Adjunct Markets

1 Trivalent Split Influenza Vaccine Market Overview
1.1 Product Definition
1.2 Trivalent Split Influenza Vaccine by Type
1.2.1 Global Trivalent Split Influenza Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Injection
1.2.3 Nasal Spray
1.3 Trivalent Split Influenza Vaccine by Application
1.3.1 Global Trivalent Split Influenza Vaccine Market Value by Application (2024 VS 2031)
1.3.2 6 Months to 3 Years
1.3.3 > 3 Years
1.4 Global Trivalent Split Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Trivalent Split Influenza Vaccine Revenue 2020-2031
1.4.2 Global Trivalent Split Influenza Vaccine Sales 2020-2031
1.4.3 Global Trivalent Split Influenza Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Trivalent Split Influenza Vaccine Market Competition by Manufacturers
2.1 Global Trivalent Split Influenza Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Trivalent Split Influenza Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Trivalent Split Influenza Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Trivalent Split Influenza Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Trivalent Split Influenza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Trivalent Split Influenza Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Trivalent Split Influenza Vaccine, Date of Enter into This Industry
2.8 Global Trivalent Split Influenza Vaccine Market Competitive Situation and Trends
2.8.1 Global Trivalent Split Influenza Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Trivalent Split Influenza Vaccine Players Market Share by Revenue
2.8.3 Global Trivalent Split Influenza Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Trivalent Split Influenza Vaccine Market Scenario by Region
3.1 Global Trivalent Split Influenza Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Trivalent Split Influenza Vaccine Sales by Region: 2020-2031
3.2.1 Global Trivalent Split Influenza Vaccine Sales by Region: 2020-2025
3.2.2 Global Trivalent Split Influenza Vaccine Sales by Region: 2026-2031
3.3 Global Trivalent Split Influenza Vaccine Revenue by Region: 2020-2031
3.3.1 Global Trivalent Split Influenza Vaccine Revenue by Region: 2020-2025
3.3.2 Global Trivalent Split Influenza Vaccine Revenue by Region: 2026-2031
3.4 North America Trivalent Split Influenza Vaccine Market Facts & Figures by Country
3.4.1 North America Trivalent Split Influenza Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Trivalent Split Influenza Vaccine Sales by Country (2020-2031)
3.4.3 North America Trivalent Split Influenza Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Trivalent Split Influenza Vaccine Market Facts & Figures by Country
3.5.1 Europe Trivalent Split Influenza Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Trivalent Split Influenza Vaccine Sales by Country (2020-2031)
3.5.3 Europe Trivalent Split Influenza Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Trivalent Split Influenza Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Trivalent Split Influenza Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Trivalent Split Influenza Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Trivalent Split Influenza Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Trivalent Split Influenza Vaccine Market Facts & Figures by Country
3.7.1 Latin America Trivalent Split Influenza Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Trivalent Split Influenza Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Trivalent Split Influenza Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Trivalent Split Influenza Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Trivalent Split Influenza Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Trivalent Split Influenza Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Trivalent Split Influenza Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Trivalent Split Influenza Vaccine Sales by Type (2020-2031)
4.1.1 Global Trivalent Split Influenza Vaccine Sales by Type (2020-2025)
4.1.2 Global Trivalent Split Influenza Vaccine Sales by Type (2026-2031)
4.1.3 Global Trivalent Split Influenza Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Trivalent Split Influenza Vaccine Revenue by Type (2020-2031)
4.2.1 Global Trivalent Split Influenza Vaccine Revenue by Type (2020-2025)
4.2.2 Global Trivalent Split Influenza Vaccine Revenue by Type (2026-2031)
4.2.3 Global Trivalent Split Influenza Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Trivalent Split Influenza Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Trivalent Split Influenza Vaccine Sales by Application (2020-2031)
5.1.1 Global Trivalent Split Influenza Vaccine Sales by Application (2020-2025)
5.1.2 Global Trivalent Split Influenza Vaccine Sales by Application (2026-2031)
5.1.3 Global Trivalent Split Influenza Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Trivalent Split Influenza Vaccine Revenue by Application (2020-2031)
5.2.1 Global Trivalent Split Influenza Vaccine Revenue by Application (2020-2025)
5.2.2 Global Trivalent Split Influenza Vaccine Revenue by Application (2026-2031)
5.2.3 Global Trivalent Split Influenza Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Trivalent Split Influenza Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Seqirus
6.1.1 Seqirus Company Information
6.1.2 Seqirus Description and Business Overview
6.1.3 Seqirus Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Seqirus Trivalent Split Influenza Vaccine Product Portfolio
6.1.5 Seqirus Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Trivalent Split Influenza Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Trivalent Split Influenza Vaccine Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Sinovac Biotech
6.4.1 Sinovac Biotech Company Information
6.4.2 Sinovac Biotech Description and Business Overview
6.4.3 Sinovac Biotech Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sinovac Biotech Trivalent Split Influenza Vaccine Product Portfolio
6.4.5 Sinovac Biotech Recent Developments/Updates
6.5 Shanghai Institute Of Biological Products Limited Liability Company
6.5.1 Shanghai Institute Of Biological Products Limited Liability Company Company Information
6.5.2 Shanghai Institute Of Biological Products Limited Liability Company Description and Business Overview
6.5.3 Shanghai Institute Of Biological Products Limited Liability Company Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Shanghai Institute Of Biological Products Limited Liability Company Trivalent Split Influenza Vaccine Product Portfolio
6.5.5 Shanghai Institute Of Biological Products Limited Liability Company Recent Developments/Updates
6.6 Zhejiang Tianyuan Bio-Pharmaceutical
6.6.1 Zhejiang Tianyuan Bio-Pharmaceutical Company Information
6.6.2 Zhejiang Tianyuan Bio-Pharmaceutical Description and Business Overview
6.6.3 Zhejiang Tianyuan Bio-Pharmaceutical Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Zhejiang Tianyuan Bio-Pharmaceutical Trivalent Split Influenza Vaccine Product Portfolio
6.6.5 Zhejiang Tianyuan Bio-Pharmaceutical Recent Developments/Updates
6.7 Changchun Institute of Biological Products
6.7.1 Changchun Institute of Biological Products Company Information
6.7.2 Changchun Institute of Biological Products Description and Business Overview
6.7.3 Changchun Institute of Biological Products Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Changchun Institute of Biological Products Trivalent Split Influenza Vaccine Product Portfolio
6.7.5 Changchun Institute of Biological Products Recent Developments/Updates
6.8 Aleph Biomedical
6.8.1 Aleph Biomedical Company Information
6.8.2 Aleph Biomedical Description and Business Overview
6.8.3 Aleph Biomedical Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Aleph Biomedical Trivalent Split Influenza Vaccine Product Portfolio
6.8.5 Aleph Biomedical Recent Developments/Updates
6.9 Adimmune Corporation
6.9.1 Adimmune Corporation Company Information
6.9.2 Adimmune Corporation Description and Business Overview
6.9.3 Adimmune Corporation Trivalent Split Influenza Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Adimmune Corporation Trivalent Split Influenza Vaccine Product Portfolio
6.9.5 Adimmune Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Trivalent Split Influenza Vaccine Industry Chain Analysis
7.2 Trivalent Split Influenza Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Trivalent Split Influenza Vaccine Production Mode & Process Analysis
7.4 Trivalent Split Influenza Vaccine Sales and Marketing
7.4.1 Trivalent Split Influenza Vaccine Sales Channels
7.4.2 Trivalent Split Influenza Vaccine Distributors
7.5 Trivalent Split Influenza Vaccine Customer Analysis
8 Trivalent Split Influenza Vaccine Market Dynamics
8.1 Trivalent Split Influenza Vaccine Industry Trends
8.2 Trivalent Split Influenza Vaccine Market Drivers
8.3 Trivalent Split Influenza Vaccine Market Challenges
8.4 Trivalent Split Influenza Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Seqirus
Sanofi
GSK
SINOVAC BIOTECH
Zhejiang Tianyuan Bio-Pharmaceutical
Changchun Institute of Biological Products
Aleph Biomedical
ADIMMUNE Corporation
Shanghai Institute Of Biological Products Limited Liability Company
List of Tables
 Table 1. Global Trivalent Split Influenza Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Trivalent Split Influenza Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Trivalent Split Influenza Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Trivalent Split Influenza Vaccine Sales (M Units) of Key Manufacturers (2020-2025)
 Table 5. Global Trivalent Split Influenza Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Trivalent Split Influenza Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Trivalent Split Influenza Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Trivalent Split Influenza Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Trivalent Split Influenza Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Trivalent Split Influenza Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Trivalent Split Influenza Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Trivalent Split Influenza Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Trivalent Split Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Trivalent Split Influenza Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Trivalent Split Influenza Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Trivalent Split Influenza Vaccine Sales by Region (2020-2025) & (M Units)
 Table 18. Global Trivalent Split Influenza Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Trivalent Split Influenza Vaccine Sales by Region (2026-2031) & (M Units)
 Table 20. Global Trivalent Split Influenza Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Trivalent Split Influenza Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Trivalent Split Influenza Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Trivalent Split Influenza Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Trivalent Split Influenza Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Trivalent Split Influenza Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Trivalent Split Influenza Vaccine Sales by Country (2020-2025) & (M Units)
 Table 27. North America Trivalent Split Influenza Vaccine Sales by Country (2026-2031) & (M Units)
 Table 28. North America Trivalent Split Influenza Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Trivalent Split Influenza Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Trivalent Split Influenza Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Trivalent Split Influenza Vaccine Sales by Country (2020-2025) & (M Units)
 Table 32. Europe Trivalent Split Influenza Vaccine Sales by Country (2026-2031) & (M Units)
 Table 33. Europe Trivalent Split Influenza Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Trivalent Split Influenza Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Trivalent Split Influenza Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Trivalent Split Influenza Vaccine Sales by Region (2020-2025) & (M Units)
 Table 37. Asia Pacific Trivalent Split Influenza Vaccine Sales by Region (2026-2031) & (M Units)
 Table 38. Asia Pacific Trivalent Split Influenza Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Trivalent Split Influenza Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Trivalent Split Influenza Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Trivalent Split Influenza Vaccine Sales by Country (2020-2025) & (M Units)
 Table 42. Latin America Trivalent Split Influenza Vaccine Sales by Country (2026-2031) & (M Units)
 Table 43. Latin America Trivalent Split Influenza Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Trivalent Split Influenza Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Trivalent Split Influenza Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Trivalent Split Influenza Vaccine Sales by Country (2020-2025) & (M Units)
 Table 47. Middle East and Africa Trivalent Split Influenza Vaccine Sales by Country (2026-2031) & (M Units)
 Table 48. Middle East and Africa Trivalent Split Influenza Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Trivalent Split Influenza Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Trivalent Split Influenza Vaccine Sales (M Units) by Type (2020-2025)
 Table 51. Global Trivalent Split Influenza Vaccine Sales (M Units) by Type (2026-2031)
 Table 52. Global Trivalent Split Influenza Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Trivalent Split Influenza Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Trivalent Split Influenza Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Trivalent Split Influenza Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Trivalent Split Influenza Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Trivalent Split Influenza Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Trivalent Split Influenza Vaccine Sales (M Units) by Application (2020-2025)
 Table 61. Global Trivalent Split Influenza Vaccine Sales (M Units) by Application (2026-2031)
 Table 62. Global Trivalent Split Influenza Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Trivalent Split Influenza Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Trivalent Split Influenza Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Trivalent Split Influenza Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Trivalent Split Influenza Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Trivalent Split Influenza Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. Seqirus Company Information
 Table 71. Seqirus Description and Business Overview
 Table 72. Seqirus Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Seqirus Trivalent Split Influenza Vaccine Product
 Table 74. Seqirus Recent Developments/Updates
 Table 75. Sanofi Company Information
 Table 76. Sanofi Description and Business Overview
 Table 77. Sanofi Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Sanofi Trivalent Split Influenza Vaccine Product
 Table 79. Sanofi Recent Developments/Updates
 Table 80. GSK Company Information
 Table 81. GSK Description and Business Overview
 Table 82. GSK Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. GSK Trivalent Split Influenza Vaccine Product
 Table 84. GSK Recent Developments/Updates
 Table 85. Sinovac Biotech Company Information
 Table 86. Sinovac Biotech Description and Business Overview
 Table 87. Sinovac Biotech Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Sinovac Biotech Trivalent Split Influenza Vaccine Product
 Table 89. Sinovac Biotech Recent Developments/Updates
 Table 90. Shanghai Institute Of Biological Products Limited Liability Company Company Information
 Table 91. Shanghai Institute Of Biological Products Limited Liability Company Description and Business Overview
 Table 92. Shanghai Institute Of Biological Products Limited Liability Company Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Shanghai Institute Of Biological Products Limited Liability Company Trivalent Split Influenza Vaccine Product
 Table 94. Shanghai Institute Of Biological Products Limited Liability Company Recent Developments/Updates
 Table 95. Zhejiang Tianyuan Bio-Pharmaceutical Company Information
 Table 96. Zhejiang Tianyuan Bio-Pharmaceutical Description and Business Overview
 Table 97. Zhejiang Tianyuan Bio-Pharmaceutical Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Zhejiang Tianyuan Bio-Pharmaceutical Trivalent Split Influenza Vaccine Product
 Table 99. Zhejiang Tianyuan Bio-Pharmaceutical Recent Developments/Updates
 Table 100. Changchun Institute of Biological Products Company Information
 Table 101. Changchun Institute of Biological Products Description and Business Overview
 Table 102. Changchun Institute of Biological Products Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Changchun Institute of Biological Products Trivalent Split Influenza Vaccine Product
 Table 104. Changchun Institute of Biological Products Recent Developments/Updates
 Table 105. Aleph Biomedical Company Information
 Table 106. Aleph Biomedical Description and Business Overview
 Table 107. Aleph Biomedical Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Aleph Biomedical Trivalent Split Influenza Vaccine Product
 Table 109. Aleph Biomedical Recent Developments/Updates
 Table 110. Adimmune Corporation Company Information
 Table 111. Adimmune Corporation Description and Business Overview
 Table 112. Adimmune Corporation Trivalent Split Influenza Vaccine Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Adimmune Corporation Trivalent Split Influenza Vaccine Product
 Table 114. Adimmune Corporation Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Trivalent Split Influenza Vaccine Distributors List
 Table 118. Trivalent Split Influenza Vaccine Customers List
 Table 119. Trivalent Split Influenza Vaccine Market Trends
 Table 120. Trivalent Split Influenza Vaccine Market Drivers
 Table 121. Trivalent Split Influenza Vaccine Market Challenges
 Table 122. Trivalent Split Influenza Vaccine Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Trivalent Split Influenza Vaccine
 Figure 2. Global Trivalent Split Influenza Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Trivalent Split Influenza Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Injection Product Picture
 Figure 5. Nasal Spray Product Picture
 Figure 6. Global Trivalent Split Influenza Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Trivalent Split Influenza Vaccine Market Share by Application: 2024 & 2031
 Figure 8. 6 Months to 3 Years
 Figure 9. > 3 Years
 Figure 10. Global Trivalent Split Influenza Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Trivalent Split Influenza Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Trivalent Split Influenza Vaccine Sales (2020-2031) & (M Units)
 Figure 13. Global Trivalent Split Influenza Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 14. Trivalent Split Influenza Vaccine Report Years Considered
 Figure 15. Trivalent Split Influenza Vaccine Sales Share by Manufacturers in 2024
 Figure 16. Global Trivalent Split Influenza Vaccine Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Trivalent Split Influenza Vaccine Players: Market Share by Revenue in Trivalent Split Influenza Vaccine in 2024
 Figure 18. Trivalent Split Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Trivalent Split Influenza Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Trivalent Split Influenza Vaccine Sales Market Share by Country (2020-2031)
 Figure 21. North America Trivalent Split Influenza Vaccine Revenue Market Share by Country (2020-2031)
 Figure 22. United States Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Trivalent Split Influenza Vaccine Sales Market Share by Country (2020-2031)
 Figure 25. Europe Trivalent Split Influenza Vaccine Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Trivalent Split Influenza Vaccine Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Trivalent Split Influenza Vaccine Revenue Market Share by Region (2020-2031)
 Figure 33. China Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Trivalent Split Influenza Vaccine Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Trivalent Split Influenza Vaccine Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Colombia Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Trivalent Split Influenza Vaccine Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Trivalent Split Influenza Vaccine Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Trivalent Split Influenza Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Trivalent Split Influenza Vaccine by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Trivalent Split Influenza Vaccine by Type (2020-2031)
 Figure 53. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Trivalent Split Influenza Vaccine by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Trivalent Split Influenza Vaccine by Application (2020-2031)
 Figure 56. Global Trivalent Split Influenza Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 57. Trivalent Split Influenza Vaccine Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Influenza Vaccine Split Virion Inactivated Quadrivalent Market Research Report 2024
Global Influenza Subunit Vaccine Market Research Report 2024
Global Multivalent Influenza Vaccines Market Research Report 2025
Global Influenza Virus Triple Test Card Market Research Report 2024
Global Trivalent Inactivated Influenza Vaccine Market Research Report 2025
Global Live Poultry Vaccine Market Research Report 2025
Global Trivalent Flu Vaccine Market Insights Forecast to 2030
Influenza Virus Vaccine H1N1 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Injection Influenza Vaccine Market Research Report 2025
Global Recombinant Influenza Vaccine Market Research Report 2024
Global Flu Vaccine Market Insights Forecast to 2030
Global Adjuvanted Influenza Vaccine Market Research Report 2024
Global Human Injection Flu Vaccine Market Research Report 2025
Global Tetravalent Influenza Virus Lysate Vaccine Market Research Report 2024
Split Influenza Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pentavalent Vaccine Market Research Report 2024
Global Influenza A Antigen Detection Kit Market Research Report 2024
Global Flu Vaccination Market Research Report 2025
Global Egg Based Flu Vaccines Market Research Report 2024
Global Injection Flu Shot Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions